Exchange: NASDAQ·Updated 02:04 PM EST

ACHV News

News
all
press releases
Achieve Life Sciences Appoints Benjamin Halladay As CFO
(RTTNews) - Achieve Life Sciences, Inc. (ACHV), a late-stage specialty pharmaceutical company, said on Thursday that it has appointed Benjamin Halladay as chief financial officer with effect from October 5. He will succeed Mark Oki, who will step down as CFO on the same day...
Nasdaq News: Markets
Achieve Life Sciences Appoints Benjamin Halladay As CFO
(RTTNews) - Achieve Life Sciences, Inc. (ACHV), a late-stage specialty pharmaceutical company, said on Thursday that it has appointed Benjamin Halladay as chief financial officer with effect from October 5. He will succeed Mark Oki, who will step down as CFO on the same day...
Nasdaq News: Markets
More News
FDA rejects Achieve Life Sciences application for cytisinicline tied to manufacturing issues, with NDA resubmission planned in Q4 2026.read more...
Benzinga
Achieve Life Sciences (NASDAQ:ACHV) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-achieve-life-sciences-inc-stock...
MarketBeat
Achieve Life Sciences (NASDAQ:ACHV) Stock Price Crosses Above Two Hundred Day Moving Average - Should You Sell...
MarketBeat
Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) has been assigned an average recommendation of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat reports...
MarketBeat
Though Achieve Life Sciences expects the FDA to reject its current cytisinicline application for the treatment of nicotine dependence, the company is hopeful of imminent approval following a resubmission in the fourth quarter.
Stocktwits
HC Wainwright reaffirmed a "buy" rating and set a $12.00 target price on shares of Achieve Life Sciences in a research report on Thursday...
MarketBeat
Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five analysts that are presently covering the firm...
MarketBeat
Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - Zacks Research dropped their FY2026 earnings per share estimates for shares of Achieve Life Sciences in a note issued to investors on...
MarketBeat

Advertisement|Remove ads.